Eurobio Scientific Société anonyme Balance Sheet Health
Financial Health criteria checks 6/6
Eurobio Scientific Société anonyme has a total shareholder equity of €178.8M and total debt of €88.2M, which brings its debt-to-equity ratio to 49.3%. Its total assets and total liabilities are €313.8M and €134.9M respectively. Eurobio Scientific Société anonyme's EBIT is €12.9M making its interest coverage ratio 4.3. It has cash and short-term investments of €86.6M.
Key information
49.3%
Debt to equity ratio
€88.17m
Debt
Interest coverage ratio | 4.3x |
Cash | €86.59m |
Equity | €178.83m |
Total liabilities | €134.94m |
Total assets | €313.77m |
Recent financial health updates
Recent updates
Eurobio Scientific Société anonyme (EPA:ALERS) Held Back By Insufficient Growth Even After Shares Climb 32%
Jul 31Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)
Jul 29Estimating The Fair Value Of Eurobio Scientific Société anonyme (EPA:ALERS)
Apr 07Is Now The Time To Put Eurobio Scientific Société anonyme (EPA:ALERS) On Your Watchlist?
Mar 08Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)
Jan 03Improved Earnings Required Before Eurobio Scientific Société anonyme (EPA:ALERS) Stock's 28% Jump Looks Justified
Dec 13Should You Be Adding Eurobio Scientific Société anonyme (EPA:ALERS) To Your Watchlist Today?
Nov 20Eurobio Scientific Société anonyme's (EPA:ALERS) Earnings Are Of Questionable Quality
May 12Financial Position Analysis
Short Term Liabilities: ALERS's short term assets (€146.7M) exceed its short term liabilities (€54.5M).
Long Term Liabilities: ALERS's short term assets (€146.7M) exceed its long term liabilities (€80.4M).
Debt to Equity History and Analysis
Debt Level: ALERS's net debt to equity ratio (0.9%) is considered satisfactory.
Reducing Debt: ALERS's debt to equity ratio has reduced from 53.2% to 49.3% over the past 5 years.
Debt Coverage: ALERS's debt is well covered by operating cash flow (26.2%).
Interest Coverage: ALERS's interest payments on its debt are well covered by EBIT (4.3x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/02 11:02 |
End of Day Share Price | 2025/01/02 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eurobio Scientific Société anonyme is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Wang Chong | Edison Investment Research |
Stephanie Lefebvre | Gilbert Dupont |
Damien Choplain | Gilbert Dupont |